Literature DB >> 11436185

Assessing systemic 11beta-hydroxysteroid dehydrogenase with serum cortisone/cortisol ratios in healthy subjects and patients with diabetes mellitus and chronic renal failure.

M Homma1, A Tanaka, K Hino, H Takamura, T Hirano, K Oka, M Kanazawa, T Miwa, Y Notoya, T Niitsuma, T Hayashi.   

Abstract

11beta-hydroxysteroid dehydrogenase (11beta-HSD), an enzyme regulating mineralocorticoid like action of glucocorticoid, oxidizes active cortisol to inactive cortisone. Impaired activity of this enzyme is associated with apparent mineralocorticoid excess (AME) syndrome and is characterized by hypertension and hypokalemia. Recent investigations suggest the presence of hypertensive subjects with low activity of 11beta-HSD. The blood concentration ratio of cortisone/cortisol reflects the overall conversion of cortisol to cortisone and may be an index to assess the systemic activity of 11beta-HSD. We evaluated the peripheral blood concentration ratio of cortisone/cortisol as a possible marker to identify subjects with hypertension thought to represent impaired 11beta-HSD activity. We compared this ratio in healthy subjects and patients with diabetes mellitus (DM) or chronic renal failure (CRF). Peripheral blood samples were collected from 69 healthy subjects, 44 DM, and 36 CRF patients in the morning (9:00 to 11:00 AM). Twenty-six DM patients (59%) and 32 CRF patients (89%) met the criteria for having hypertension. Serum cortisol and cortisone concentrations were determined by high performance liquid chromatography (HPLC). All values for serum cortisone and cortisol levels were within the normal range. Serum cortisone/cortisol ratio in the healthy subjects was distributed with a range of 0.113 to 0.494 (median, 0.243). Compared with healthy subjects, DM and CRF patients had significantly low (P <.01) serum cortisone/cortisol levels (median, 0.188 [range, 0.092 to 0.313] in DM and 0.088 [range, 0.031 to 0.140] in CRF). Bimodal distribution of cortisone/cortisol, found in DM patients with hypertension, represented high- and low-ratio groups around the border of the ratio 0.2. Kidney function, DM duration, and complications varied between the high- and low-ratio groups. The low ratio group (<0.2), whose 11beta-HSD activity was considered low, had an increase in blood urea nitrogen (BUN) levels and experienced nephropathy, neuropathy, retinopathy, and prolonged DM duration when compared with the group with a ratio greater than 0.2. The data suggest that the serum cortisone/cortisol ratio reflects the change in 11beta-HSD activity and is dependent kidney function. This is a possible marker to evaluate glucocorticoid excess hypertension observed in DM and CRF patients. Copyright 2001 by W.B. Saunders Company

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11436185     DOI: 10.1053/meta.2001.24213

Source DB:  PubMed          Journal:  Metabolism        ISSN: 0026-0495            Impact factor:   8.694


  9 in total

Review 1.  Tissue-specific dysregulation of 11beta-hydroxysteroid dehydrogenase type 1 and pathogenesis of the metabolic syndrome.

Authors:  P Putignano; F Pecori Giraldi; F Cavagnini
Journal:  J Endocrinol Invest       Date:  2004-11       Impact factor: 4.256

2.  Portal and peripheral cortisol levels in obese humans.

Authors:  W Aldhahi; E Mun; A B Goldfine
Journal:  Diabetologia       Date:  2004-04-17       Impact factor: 10.122

3.  Biomedical evaluation of cortisol, cortisone, and corticosterone along with testosterone and epitestosterone applying micellar electrokinetic chromatography.

Authors:  Tomasz Bączek; Ilona Olędzka; Lucyna Konieczna; Piotr Kowalski; Alina Plenis
Journal:  ScientificWorldJournal       Date:  2012-03-12

4.  Effect of Luteolin on 11Beta-Hydroxysteroid Dehydrogenase in Rat Liver and Kidney.

Authors:  Lei Tang; Bin Deng; Lijuan Shi; Binghua Wei; Bin Ren; Xiaohua Fu
Journal:  Evid Based Complement Alternat Med       Date:  2015-06-25       Impact factor: 2.629

5.  Liquorice-induced hypokalaemia in patients treated with Yokukansan preparations: identification of the risk factors in a retrospective cohort study.

Authors:  Saori Shimada; Tetsuaki Arai; Akira Tamaoka; Masato Homma
Journal:  BMJ Open       Date:  2017-06-15       Impact factor: 2.692

6.  A Liquid Chromatography/Tandem Mass Spectometry Profile of 16 Serum Steroids, Including 21-Deoxycortisol and 21-Deoxycorticosterone, for Management of Congenital Adrenal Hyperplasia.

Authors:  Jean Fiet; Yves Le Bouc; Jérôme Guéchot; Nicolas Hélin; Marie-Anne Maubert; Dominique Farabos; Antonin Lamazière
Journal:  J Endocr Soc       Date:  2017-02-10

7.  Gender-Specific Independent and Combined Effects of the Cortisol-to-Cortisone Ratio and 11-Deoxycortisol on Prediabetes and Type 2 Diabetes Mellitus: From the Henan Rural Cohort Study.

Authors:  Xue Liu; Jingjing Jiang; Xiaotian Liu; Zhicheng Luo; Yan Wang; Xiaokang Dong; Dandan Wei; Wenqian Huo; Songcheng Yu; Linlin Li; Shuna Jin; Chongjian Wang; Zhenxing Mao
Journal:  J Diabetes Res       Date:  2019-06-02       Impact factor: 4.011

8.  Simultaneous determination of cortisol and cortisone from human serum by liquid chromatography-tandem mass spectrometry.

Authors:  Sanghoo Lee; Hwan-Sub Lim; Hye-Jin Shin; Seol-A Kim; Jimyeong Park; Hyun-Chul Kim; Hyogyeong Kim; Hyung Joo Kim; Yun-Tae Kim; Kyoung-Ryul Lee; Young-Jin Kim
Journal:  J Anal Methods Chem       Date:  2014-03-06       Impact factor: 2.193

9.  Glucocorticoid activation by 11β-hydroxysteroid dehydrogenase enzymes in relation to inflammation and glycaemic control in chronic kidney disease: A cross-sectional study.

Authors:  Michael S Sagmeister; Angela E Taylor; Anthony Fenton; Nadezhda A Wall; Dimitrios Chanouzas; Peter G Nightingale; Charles J Ferro; Wiebke Arlt; Paul Cockwell; Rowan S Hardy; Lorraine Harper
Journal:  Clin Endocrinol (Oxf)       Date:  2018-11-15       Impact factor: 3.478

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.